Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19734188 | 1.00 | NCF1 (0.30) | NCF1 | |
| SCHEMBL19734185 | 1.00 | NCF1 (0.30) | NCF1 | |
| SCHEMBL19734190 | 0.91 | — | — | |
| SCHEMBL19734186 | 0.91 | — | — | |
| SCHEMBL19734187 | 0.91 | — | — | |
| SCHEMBL19734191 | 0.89 | — | — | |
| SCHEMBL19734189 | 0.89 | — | — | |
| SCHEMBL19734192 | 0.89 | — | — | |
| SCHEMBL16659546 | 0.84 | DRD4 (0.31) | — | |
| SCHEMBL26052446 | 0.84 | DRD4 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021046286-A1 | HEPATITIS B ANTIVIRAL AGENTS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2021-03-11 | — | — | WO | disclosed |
| US-20170362217-A1 | Substituted Piperidine Compounds | Epizyme, Inc. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20140128390-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | disclosed |
| US-20080214565-A1 | Oxazolidinone Derivatives as Antimicrobials | RANBAXY LABORATORIES LIMITED (IN) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362217-A1 | Substituted Piperidine Compounds | SMYD3, SMYD2, SNRPD3 | NCF1 2077/4885 |
| US-20080214565-A1 | Oxazolidinone Derivatives as Antimicrobials | OXA1L, SDHA, PDK4 | NCF1 2072/4885 |
| US-20140128390-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, PRKCH, PRKACA | NCF1 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.